Schedule 13D ownership disclosure

Compass Therapeutics Inc

Common Stock, par value $0.0001 per share · CUSIP: 20454B104

Event date: 2025-08-14

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Commander Aggregator, LPReported CIK 0001953093

    Shares: 7,788,150 · Class: 4.5%

  • Enavate Sciences, LPReported CIK 0001953098

    Shares: 7,788,150 · Class: 4.5%

  • Enavate Sciences GP, LLCReported CIK 0001953107

    Shares: 7,788,150 · Class: 4.5%

  • Enavate Sciences Holdings, LLC

    Shares: 7,788,150 · Class: 4.5%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000950170-25-109869
Form type
SCHEDULE 13D/A
Filer
Commander Aggregator, LP
CIK
CIK 1953093
Filed
Aug 18, 2025
Reporting period
Aug 14, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub